Literature DB >> 17515484

Kentucky hepatoma: epidemiologic variant or same problem in a different region?

Robert C G Martin1, Jennifer Loehle, Charles R Scoggins, Kelly M McMasters.   

Abstract

BACKGROUND: Hepatitis and cirrhosis are common etiologic factors in hepatocellular carcinoma (HCC) in the United States. However, noncirrhotic, nonfibrotic HCC has been recognized more frequently in Kentucky. The aim of this study was to evaluate the epidemiologic features of this variant of HCC. HYPOTHESIS: Kentucky hepatoma, defined as a noncirrhotic, nonfibrotic, hepatitis-negative HCC, occurs in an older population with more favorable preoperative factors when compared with other patients with HCC.
DESIGN: A prospective review of our 1002 hepatopancreaticobiliary patients, the Kentucky Cancer Registry, and the Surveillance, Epidemiology, and End Results database.
SETTING: An academic referral center. PATIENTS: All patients with HCC treated from January 1, 1999, through September 30, 2005, were reviewed for clinicopathologic factors, recurrence, and outcome.
RESULTS: In a review of the region's 703 patients with HCC, we have seen a 4-fold increase in age-specific HCC diagnosis, with the most rapid increase seen in the 60- to 69-year-old age group. In our institution's 103 patients with HCC, 62 (60.2%) were without hepatitis or cirrhosis. These noncirrhotic, hepatitis-free patients were found to be significantly older (70 vs 55 years; P = .001), to be more often female (40.3% vs 24.4%; P = .01), to have a larger tumor size (6.5 vs 3.9 cm; P = .004), to have fewer liver lesions (1 vs 3; P = .22), and to more frequently undergo surgical therapy (75.6% vs 53.8%; P = .01) than the patients with cirrhosis or hepatitis (n = 41).
CONCLUSIONS: A larger percentage of the patients with HCC seen in our region are significantly different from those in other reports throughout the United States in preoperative clinical and pathologic presentation. The reason for this change is as yet unknown, but the incidence continues to rise annually.

Entities:  

Mesh:

Year:  2007        PMID: 17515484     DOI: 10.1001/archsurg.142.5.431

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  Multi-disciplinary Concurrent Management of Recurrent Hepatocellular Therapy is Superior to Sequential Therapy.

Authors:  Tyler D Fields; Prejesh Philips; Charles R Scoggins; Cliff Tatum; Lawrence Kelly; Kelly M McMasters; Robert C G Martin
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

2.  Hepatocellular carcinoma in patients with no identifiable risk factors.

Authors:  Caitlin A McIntyre; Joanne F Chou; Mithat Gonen; Jinru Shia; Maya Gambarin-Gelwan; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Jeffrey A Drebin; William R Jarnagin; Michael I D'Angelica
Journal:  HPB (Oxford)       Date:  2020-06-24       Impact factor: 3.647

3.  Preoperative Alpha-Fetoprotein Has No Prognostic Role in Small Hepatocellular Carcinoma in Non-Cirrhotic Patients After Surgical Resection.

Authors:  Tian-Ming Gao; Dou-Sheng Bai; Jian-Jun Qian; Ping Chen; Sheng-Jie Jin; Guo-Qing Jiang
Journal:  Turk J Gastroenterol       Date:  2021-02       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.